Acute and subacute functional effects of relaxin-2 on human mammary artery by Francisco Pereira Gonçalves
2016/2017
Francisco Pereira Gonçalves
Acute and subacute functional 
effects of relaxin-2 on human 
mammary artery/
Efeitos funcionais agudos e 
subagudos da relaxina-2 na artéria 
mamária humana
março, 2017
Mestrado Integrado em Medicina
Área: Medicina básica (FOS 3.1)
Fisiologia 
Tipologia: Dissertação
Trabalho efetuado sob a Orientação de:
Professor Doutor Paulo Castro Chaves
E sob a Coorientação de:
Professor Doutor Adelino Leite Moreira
Trabalho organizado de acordo com as normas da revista: Peptides
Francisco Pereira Gonçalves
Acute and subacute functional effects of 
relaxin-2 on human mammary artery/
Efeitos funcionais agudos e subagudos da 
relaxina-2 na artéria mamária humana
março, 2017
Projeto de Opção do 6º ano - DECLARAÇÃO DE INTEGRIDADE 
 
 
 
Eu, Francisco Pereira Gonçalves, abaixo assinado, nº mecanográfico 201107394, estudante do 6º ano 
do Ciclo de Estudos Integrado em Medicina, na Faculdade de Medicina da Universidade do Porto, 
declaro ter atuado com absoluta integridade na elaboração deste projeto de opção.  
Neste sentido, confirmo que NÃO incorri em plágio (ato pelo qual um indivíduo, mesmo por omissão, 
assume a autoria de um determinado trabalho intelectual, ou partes dele). Mais declaro que todas as 
frases que retirei de trabalhos anteriores pertencentes a outros autores, foram referenciadas, ou 
redigidas com novas palavras, tendo colocado, neste caso, a citação da fonte bibliográfica. 
 
Faculdade de Medicina da Universidade do Porto, 09/03/2017 
 
Assinatura conforme cartão de identificação:  
 
Projecto de Opção do 6º ano – DECLARAÇÃO DE REPRODUÇÃO 
 
 
NOME 
Francisco Pereira Gonçalves 
 
NÚMERO DE ESTUDANTE     DATA DE CONCLUSÃO 
201107394 09-03-2017 
 
DESIGNAÇÃO DA ÁREA DO PROJECTO 
Medicina Básica (FOS 3.1) - Fisiologia 
 
TÍTULO DISSERTAÇÃO 
Acute and subacute functional effects of relaxin-2 on human mammary artery 
 
ORIENTADOR  
Paulo Castro Chaves 
 
COORIENTADOR 
Adelino Leite Moreira 
 
ASSINALE APENAS UMA DAS OPÇÕES: 
É AUTORIZADA A REPRODUÇÃO INTEGRAL DESTE TRABALHO APENAS PARA EFEITOS DE INVESTIGAÇÃO, 
MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE COMPROMETE. 
 
É AUTORIZADA A REPRODUÇÃO PARCIAL DESTE TRABALHO (INDICAR, CASO TAL SEJA NECESSÁRIO, Nº 
MÁXIMO DE PÁGINAS, ILUSTRAÇÕES, GRÁFICOS, ETC.) APENAS PARA EFEITOS DE INVESTIGAÇÃO, MEDIANTE 
DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE COMPROMETE. 
 
DE ACORDO COM A LEGISLAÇÃO EM VIGOR, (INDICAR, CASO TAL SEJA NECESSÁRIO, Nº MÁXIMO DE PÁGINAS, 
ILUSTRAÇÕES, GRÁFICOS, ETC.) NÃO É PERMITIDA A REPRODUÇÃO DE QUALQUER PARTE DESTE TRABALHO. 
 
X 
 
Faculdade de Medicina da Universidade do Porto, 09/03/2017 
Assinatura conforme cartão de identificação:  
 
  
Acute and subacute functional effects of 
relaxin-2 on human mammary artery 
 
 
Francisco Gonçalves1,2, Rafael Martins,1,2, Luís Mendonça1,2, Tiago Laundos 
Santos3,4, Mariana Pintalhão1,2,5, Francisco Vasques Nóvoa1,2,5, Mário Jorge 
Amorim6, Paulo Pinho6, Diana Nascimento 3,4, Adelino Leite Moreira1,2,6, Paulo 
Castro Chaves1,2,5 
 
 
 
1 - Departamento de Cirurgia e Fisiologia, Universidade do Porto, Portugal. 
2 - Unidade de Investigação Cardiovascular, Portugal. 
3 - Instituto de Engenharia Biomédica (INEB), Universidade do Porto, Portugal. 
4 - Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Portugal. 
5 - Internal Medicine Department, São João Hospital Centre, Porto, Portugal. 
6 - Cardiothoracic Surgery Department, São João Hospital Centre, Porto, Portugal. 
 
 
Endereço para correspondência: 
Professor Doutor Paulo Castro-Chaves 
Departamento de Cirurgia e Fisiologia, 
Faculdade de Medicina da Universidade do Porto 
Alameda Professor Hernâni Monteiro; 4200-319 Porto, Portugal 
Tel.: +351 225508452; Fax: +351 225519194; E.mail: pchaves@med.up.pt
Acute and subacute functional effects of   Francisco Gonçalves 
relaxin-2 on human mammary artery   March 2017 
ABSTRACT 
Introduction: Despite classically associated with pregnancy, relaxin is a hormone with pleiotropic 
properties and an increasingly unveiled role in the pathophysiology of several cardiovascular 
diseases. Previous clinical trials have explored its therapeutic role on acute heart failure. However, 
the exact actions of relaxin on the human vascular territory are scarcely known. 
Purposes: To study the acute and subacute functional effects of relaxin-2 on the vasoreactivity of 
the human mammary artery (HMA). To assess the expression of RXFP1, its main receptor, in this 
vascular territory. 
Methods: HMA from 37 patients subjected to coronary artery bypass graft surgery (average age 69.3 
years; 7 female) were sectioned into 2mm rings and mounted on a myograph (DMT myograph 
system). On one protocol, the vessels were exposed to increasing concentrations of relaxin (10-10-
10-7M) or vehicle after pre-contraction with phenylephrine (10-5M), n=5. On a different protocol, 
the rings were treated for 24h with relaxin (10-7M) or vehicle and afterwards subjected to 
increasing concentrations of vasoconstrictors (10-9-10-5 M) - phenylephrine (n=8), endothelin-1 
(n=6) and angiotensin II (n=11) – and of vasodilators (10-10-10-5 M) - acetylcholine (n=8) and sodium 
nitroprusside (n=11). Vessel rings were also incubated for 24h with relaxin or vehicle after 
endothelium removal, and their response to nitroprusside evaluated (10-10-10-5 M; n=7). 
Immunofluorescence labelling of RXFP1 was performed along with labelling for CD31 (endothelial 
cells) and α smooth muscle actin (smooth muscle cells). Functional responses are expressed as 
mean±standard error (%). 
Results: After acute exposure to relaxin, no differences in the developed active tension were 
observed between relaxin or vehicle treated groups. Following 24h treatment with relaxin or 
vehicle, vascular viability and the vasoconstrictor effects of phenylephrine, endothelin-1 and 
angiotensin II were similar between groups. However, vessel rings treated with relaxin showed 
higher relaxation when compared to vehicle treated rings, both in response to acetylcholine 
(59.1±6.1% vs 46.2±6.2%; p<0.01) and nitroprusside (128.9±4.8% vs 118.7±5.1% p<0.05). The 
higher response to nitroprusside was preserved when treatment with relaxin followed 
endothelium removal (143.3±4.1% vs 132.8±3.3%; p<0.01). Immunofluorescence showed labelling 
for RXFP1 on smooth muscle and endothelial cells. 
Conclusion: Treatment with relaxin-2 for 24h potentiates HMA vasodilatation without interfering 
with the effects of several vasoconstrictors, and this effect is at least partially independent of the 
endothelium. We have also identified for the first time the presence of RXFP1 on the 
endothelium and smooth muscle cells of HMA. Besides shedding further light on relaxin’s role on 
human vascular physiology, the present work may have implications in the understanding of 
HMA’s physiology, an important conduct for coronary revascularization procedures. 
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INTRODUCTION 
Relaxin-2 is a peptide hormone initially described for its effects on the female reproductive 
tract during pregnancy, and is responsible as well for mediating the cardiovascular adaptations 
that occur during this period, inclusively through its actions on the systemic and renal vasculature. 
[1-3] 
In the past two decades, growing evidence has attributed relaxin pleiotropic effects on the 
cardiovascular system. This hormone may play an import role on the pathophysiology of heart 
failure, hypertension and cardiac ischemic disease. [4-6] Effectively, several studies point towards 
compensatory production and release of relaxin by the myocardium during heart failure, and 
indeed plasmatic levels of relaxin correlate with clinical and echocardiographic parameters of right 
side heart overload. [7] 
Additionally, relaxin has been evaluated as a possible therapeutic weapon in conditions 
such as heart failure, hypertension, pre-eclampsia and peripheral vascular disease. [2] The RELAX-
AHF randomized clinical trial has demonstrated superiority of relaxin on dyspnoea relief and 
mortality reduction at 180 days in relation to placebo, in an acute heart failure setting. [8] In the 
context of cardiac ischemic disease, the demonstration of beneficial effects on the myocardial 
ischemia-reperfusion lesion both on a pig model subject to anterior descent artery occlusion [9] 
and on rat cardiomyocytes culture [10], may signal further therapeutic usefulness on coronary 
heart disease and acute myocardial infarction. 
Laboratory studies on animal models attribute relaxin angiogenic, antioxidant, anti-
inflammatory, antifibrotic and vasodilator actions [4, 5], that may constitute the basis of its 
cardioprotective potential. The vascular effects of relaxin, mediated by its main receptor, RXFP1, 
seem to occur through a rise in nitric oxide, with a probable involvement of metalloproteinases, 
ET-B receptor signalling, extracellular matrix modifications and possibly VEGF signalling. [11] 
However, the effects and mechanisms of action are markedly heterogenous between different 
vascular territories and studies in human are scarce. Indeed, several aspects of relaxin’s action on 
human vascular tissue await full characterization. [12] 
Internal thoracic artery, or mammary artery (MA), is the preferred conduct for coronary 
artery bypass graft (CABG) surgery [13, 14], and is characterized by its relative resistance to 
atherosclerosis and endothelial dysfunction. [15, 16] These characteristics together with its clinical 
relevance justify the pertinence of further unravelling the factors that modulate its vasoreactivity. 
The present work aims to contribute for the enlightenment of relaxin’s role in human 
vascular physiology, with the main goals of characterizing its acute and subacute effects on MA 
vasoreactivity, the relevance of several clinical characteristics for the said effects and lastly to 
assess the presence of RXFP1, relaxin’s main receptor, in this vascular territory.  
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METHODS 
Sample collection and dissection of vascular rings   
Spare MA segments were collected by the Cardiothoracic Surgery Team during 37 CABG 
procedures. Following collection, the segments were transported to the laboratory within 15 
minutes in a physiological Krebs solution (T: 4ºC), with the following composition (mM): 130 NaCl; 
4.7 KCl; 14.9 NaHCO3; 1.18 KH2PO4; 5.5 glucose; 1.17 MgSO4·7H2O e 1.6 CaCl2·2H2O. In the 
laboratory the adjacent connective tissue was removed and the vessel was sectioned into rings 
with 2 mm of length each. The patients included in the study were characterized in terms of 
demographic characteristics, past medical history and medication prescribed. The project was 
approved by the local Ethical Committee. The vascular rings obtained were used for both the 
functional and immunofluorescence protocols described below. 
Functional Protocols 
Experimental Preparation 
Each functional protocol proceeded using 4 vascular rings obtained from a single patient. 
The rings were horizontally mounted in a myograph (Multi Wire Myograph System Model 620M - 
DMT®) in Krebs solution (32ºC, pH 7.40), bubbling with a gaseous mixture (95% O2; 5% CO2). After 
normalization to an effective transmural pressure of 100 mmHg, per a previously described 
protocol [17], the rings stabilized during 60 min. Following this period, the vessel viability was 
assessed through inciting the maximum contractile response to KCl (0,1M). After washing and new 
stabilization for 30 min, the response to several vasoactive peptides was determined for each ring. 
Data was continuously acquired and digitally stored (PowerLab 4/30 ADInstruments). The 
following parameters were recorded: dimensions (segment and rings lengths and internal 
circumference, in μm), tension (T, mN/mm) and effective transmural pressure (ERTP, kPa). 
 
1- Influence of the acute treatment with relaxin on MA’s vasoreactivity  
To study the immediate action of relaxin on MA, the rings obtained from the MA of 5 
different patients were pre-contracted with phenylephrine (10-5M) and exposed to increasing 
concentrations (10-10 -10-7M) of relaxin-2 (SRP3147, Sigma-Aldrich®) or vehicle. (Figure 1 - 1) 
 
2 – Influence of the subacute treatment with relaxin on MA’s vasoreactivity 
For this subset of protocols, which aimed to assess the influence of the preceding 
treatment with relaxin on MA’s response to several vasoactive peptides, the vascular rings 
obtained from 30 different patients were randomized to incubation for 24 hours with relaxin (10-
7M) or vehicle in DMEM culture medium (37ºC; 5% CO2), preceding its assembly in the myograph. 
Following the normalization and contraction in response to KCl, described above, the rings were 
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subjected to the action of several vasoconstrictors (phenylephrine hydrochloride, endhotelin-1, 
human angiotensin II) or vasodilators (acetylcholine chloride, sodium nitroprusside). All the 
reagents were acquired from Sigma-Aldrich®. 
 
Figure 1 – Study design: 1 –  Influence of the acute treatment with relaxin on mammary artery’s 
(MA’s) vasoreactivity; 2 – Influence of the subacute treatment with relaxin on MA’s vasoreactivity, 2.1 
vasoconstrictor response, 2.2 – vasodilator response, 2.3 – vasodilator response, in the absence of 
endothelium; Phe – phenylephrine, ET – endothelin-1, Ang II – angiotensin II, NO – nitroprusside, Ach – 
acetylcholine. 
 
2.1 vasoconstrictor response 
In these protocols, the vascular rings were subjected to increasing concentrations (109 
-10-5 M) of phenylephrine (n=8 patients), endothelin-1 (n=6) or angiotensin II (n=11). (Figure 
1 - 2.1) 
 
2.2 – vasodilator response  
In these protocols, the vascular rings were subjected to a pre-contraction with 
phenylephrine (10-9M - 10-5M) and then to increasing concentrations (10-10-10-5 M) of 
acetylcholine (n=8 patients) or sodium nitroprusside (n=11). (Figure 1 – 2.2). 
 
2.3 – vasodilator response in the absence of endothelium 
The vascular rings obtained from 7 different patients were subjected to mechanical 
endothelium removal using a silk suture wire (2.0), before proceeding to incubation with 
relaxin of vehicle as previously described. Vasocontraction was elicited using phenylephrine 
(10-9M - 10-5M) and followed by addition of increasing concentrations of nitroprusside (10-
10-10-5 M). Subsequently, a dose-response curve for acetylcholine (10-10-10-5 M) following 
contraction with phenylephrine (10-5M) was determined in order to confirm the absence of 
endothelium, as previously described. [17, 18] (Figure 1 – 2.3) 
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Immunofluorescence protocols 
Vascular rings (see “Sample collection and dissection of vascular rings” above) were fixed 
overnight in 10% neutral buffered formalin and embedded in paraffin. Histological 3 μm sections 
were rehydrated and subjected to an antigen retrieval protocol with Tris/EDTA (pH=9.0; 96ºC; 35 
min) and to treatment with Sudan Black B (0.5% (m/V) in ethanol 70%(V/V); room temperature; 5 
min). Lastly, the sections were submitted to permeabilization with Triton X-100 (0.2%; room 
temperature; 5 min). 
 
RXFP1 location 
Two MA rings from different patients were used for identification of RXFP1. Following 
treatment described above, the sections were incubated overnight with a primary antibody for the 
RXFP1 receptor (1:200; HPA027067, rabbit polyclonal; Sigma-Aldrich), primary antibody for CD31 
(1:250; SC-1506, goat polyclonal, Santa Cruz Biotechnology) and primary antibody for smooth 
muscle actin (1:400; A5228, mouse monoclonal, Sigma-Aldrich), at 4º C. Following washing, they 
were incubated with the corresponding secondary antibodies for 1 hour (A31573 donkey anti-
rabbit; A21202 donkey anti-mouse; A11057 donkey anti-goat, respectively) and incubated in a 4’,6-
diamidino-2-phenylindole medium (DAPI) prior to cover slip placement. The specificity of the 
immunostaining was assessed by omission of the primary antibodies. The images were obtained 
with wide-field microscopy (DMI6000B Microscope; Leica, Heidelberg, Germany), with a 63x 
amplification (1.3 NA).  
 
Endothelium removal confirmation 
Two out of all the rings subjected to mechanical endothelium removal were randomly 
selected for an immunofluorescence protocol. This protocol followed the steps described 
previously, but was performed with only the primary antibodies for CD31 and sma. Two rings not 
subjected to endothelium removal were used as positive controls. 
 
Statistical analysis 
The tensions achieved with vasoconstriction in response to KCl were expressed in Active 
Tension (AT, mN/mm). For all other vasoconstrictor responses, the instantaneous active tension 
was expressed as the percentage of the response to KCl (AT vasoconstrictor/KCl, %). For the 
vasodilator responses, the instantaneous active response was expressed as the percentage of the 
active tension generated in response to phenylephrine (AT vasodilator/PheMax, %). The results are 
presented as mean±standard error. Two-way repeated measures ANOVA was used for the 
comparison between the tension developed in the relaxin treated group and the vehicle treated 
one. P<0,05 was considered statistically significant.  
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RESULTS 
Functional protocols 
 
Population characterization 
MA segments from 37 CABG were used. The demographic characteristics and relevant clinical 
data for these patients are presented in Table 1. The average age was 69.3 years (from 52 to 83 
years old) and 7 patients were female (18.9%). No influence of any of these variables, including 
gender, was observed on the effect of relaxin on human MA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 – Characterization of the population (ACEI: angiotensin converting enzyme inhibitors; ARA: 
angiotensin AT1 receptor antagonists) 
 
1 - Influence of the acute treatment with relaxin on MA’s vasoreactivity  
As Figure 2 represents, increasing concentrations (10-10-10-7M) of relaxin did not have an acute 
vasodilatory effect on MA pre-contracted with phenylephrine, and the AT was similar between the 
relaxin and vehicle-treated groups. 
 
 
 
 
 
 
Age, average (range) 69.3 (52-83) 
Female, n (%) 7 (18.9) 
Hypertension, n (%) 33 (89.2) 
Diabetes mellitus, n (%) 21 (56.8) 
Smoking (current/previous), n (%) 13 (35.1) 
Statins, n (%) 26 (70.3) 
ACEI and/or ARA, n (%) 26 (70.3) 
Diuretics, n (%) 12 (32.4) 
Nitrates, n (%) 11 (25.7) 
Β Blockers, n (%) 21 (56.8) 
Calcium channel blockers, n (%) 13 (35.1) 
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Figure 2 – Evaluation of the influence of the 
acute treatment with relaxin-2 (10-10 M a 10-5 M) 
or vehicle in MA pre-contracted with 
phenylephrine (10-9 - 10-5 M), n=5; AT – active 
tension: percentage (%) of the response to 0,1 M 
KCl, expressed as average ± standard error. 
 
 
2 – Influence of the subacute treatment with relaxin on MA’s vasoreactivity 
Globally, the AT (mN/mm) generated in response to KCl (0,1M) was similar for the vessels in 
the relaxin or vehicle-treated groups (15.75±2.32 mN vs 16.85±3.33 mN, respectively; n=32), 
reflecting comparable vascular viability between groups (Figure 3 – A). 
 
2.1 vasoconstrictor response 
No differences between the active tension developed by relaxin or vehicle treated 
groups was found for any of the studied vasoconstrictors. The average AT generated in 
response to the maximum concentration of phenylephrine (10-5 M; n=8; Figure 3- B) was 59.0± 
5.4% for the relaxin treated rings and 55.6±4,9% for vehicle treated group. Only the maximum 
used concentration of endothelin generated vasoconstriction (10-5 M; n=6; Figure 3 - C), 
corresponding to an AT for the relaxin treated rings of 36.8±4.7% and for the vehicle treated 
rings of 34.2±5.8%. The dose-response curves for the relaxin or vehicle treated groups were 
similar, with no significantly different AT values for any of the used concentrations (Figure 3-
D). 
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Figure 3 – Vasoconstrictor response after incubation for 24h with either relaxin-2 (10-7 M) or vehicle; AT 
(active tension - average ± standard error) expressed as mN/mm (graphic A) or as percentage (%) of the 
response to 0,1 M KCl (graphics B, C and D); A – Response to 0,1M KCl, n=19; B – Response to phenylephrine 
(Phe - 10-9 - 10-5 M), n=8; C – Response to endothelin-1 (ET - 10-5 M), n=6; D – Response to angiotensin II 
(AngII - 10-9  - 10-5 M), n=11. 
 
 
2.2 – vasodilator response 
The relaxin pre-treated vascular rings showed a superior vasodilatory response to 
acetylcholine when compared with the vehicle treated group. Effectively, when the rings were 
incubated with relaxin, the total AT decrease following exposure to the maximum dose of 
acetylcholine (10-5 M) was 59.1±6.1%, compared to 46.2±6.2% for the rings incubated with 
vehicle (p<0.01; Figure 4 - A). Similarly, the vasodilator response to nitroprusside was higher 
in the relaxin treated rings, with a total AT decrease of 128.9±4.8% after addition of the 
highest dose of nitroprusside (10-5M), compared to only 118.7±5.1% for the vehicle treated 
rings (p<0.05; Figure 4 - B). 
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Figure 4 – Vasodilator response after incubation for 24h with either relaxin-2 (10-7 M) or vehicle; AT (active 
tension - average ± standard error) expressed as percentage (%) of the response to phenylephrine (10-5 M); 
A – Response to acetylcholine (Ach - 10-10 M - 10-5 M), n=8; B – Response to nitroprusside (NO - 10-10 M - 10-
5 M), n=11; * p<0.05, vs vehicle. 
 
2.3 – vasodilator response in the absence of endothelium 
Vasodilator response to concentrations of 10-7 M, 10-6 M and 10-5 M of nitroprusside 
was higher after incubation with relaxin with prior endothelium removal, when compared to 
vehicle. For the maximum concentration of nitroprusside, the total decrease in AT for the 
relaxin treated rings was 143.3±4.1%, with a decrease of only 132.8±3.3% by the vehicle 
treated rings (p<0.01; Figure 5). 
 
 
Figure 5 -  Vasodilator response to nitroprusside (NO - 10-10 M - 10-5 M), n=7, after endothelium removal 
followed by incubation for 24h with either relaxin-2 (10-7 M) or vehicle; AT (active tension - average ± 
standard error) expressed as percentage (%) of the response to phenylephrine (10-5 M); * p<0.05, vs vehicle. 
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Immunofluorescence protocols 
Endothelium removal confirmation 
The rings not subjected to endothelium removal (positive controls) showed immunostaining 
for CD31, reflecting the presence of endothelial cells. The rings subjected to endothelium removal 
showed no labelling for CD31 (Figure 6).  
 
 
Figure 6 - Endothelium removal confirmation; A – positive control ring with endothelial cells labelled by 
CD31 (arrows); B –AM ring after mechanical endothelium removal (no labelling for CD31). 
 
RXFP1 location 
The immunofluorescence protocol showed specific labelling for RXFP1 in the AM of 2 patients 
and demonstrated its colocalization with CD31 and sma, supporting its expression by both human 
MA endothelial and smooth muscle cells (Figure 7). 
 
Figure 7 - RXFP1 location on MA; A -  immunostaining for RXFP1 superimposed with labelling for 
endothelial cells (CD31) and smooth muscle cells (alpha smooth muscle actin – α-sma); B – nuclear labelling 
(DAPI); C – Labelling for RXFP1; D – Labelling for α-sma; E – Labelling for CD31.  
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DISCUSSION AND CONCLUSION 
 
This study constitutes the first description of relaxin’s functional effects on the human MA, a 
crucial vascular territory for the surgical approach to ischemic cardiomyopathy. In the present 
work, MA’s response to relaxin was assessed in two different settings. In the first protocol, we 
showed that relaxin was not able to induce, per se, a vasodilatory response by MA in the in vitro 
conditions described. However, in the second set of protocols, we observed that previous 
incubation for 24h with relaxin potentiated MA’s vasodilation in response both to acetylcholine, 
which effects are mediated by the endothelium, and to nitroprusside, which has a direct effect on 
the smooth muscle, without an apparent concomitant increase in the vasoconstrictor response to 
either phenylephrine, endothelin-1 or angiotensin II. In this study we also describe, for the first 
time, RXFP1’s expression on the endothelial and smooth muscle cells of this artery. 
RXFP1, the human relaxin-2 receptor, is distributed in a similar way to its ligand, compatible 
with a predominantly paracrine or autocrine actions of relaxin [11] and with the usually low or 
even undetectable relaxin plasmatic levels in healthy individuals. In rat, this receptor is distributed 
in a heterogenous way between the smooth muscle cells and the endothelial cells accordingly to 
the vascular territory considered: it is mainly localized in the smooth muscle cells in femoral artery 
and vein and pulmonary arterioles and mainly in endothelial cells in aorta, cava vein and 
mesenteric artery and veins. [19] The expression of RXFP1’s mRNA was identified in subcutaneous 
human arteries [12] and in several human vascular cells, namely human umbilical artery and vein 
endothelial and smooth muscle cells, even though the protein was not expressed in the membrane 
of umbilical artery endothelial cells. [20] RXFP1 probably mediates the clear majority of relaxin’s 
vasodilatory actions [11] and this study demonstrates its unequivocal expression on the 
endothelial and smooth muscle layers, both of which are thus putative targets for relaxin. 
Currently, information is lacking regarding relaxin’s action and respective mechanisms of 
signalling on human tissues with cardiovascular significance that endogenously express RXFP1. 
Despite this, the acute modulation of the vascular function by relaxin is already described in vivo 
in the human. In the clinical trial RELAX-AHF the group of patients treated with an intravenous 
infusion of relaxin showed a higher decrease of the systolic arterial pressure [8] and a previous 
clinical trial revealed hemodynamic changes mostly within 30 minutes of infusion of relaxin in 
patients with acute heart failure, namely reduction of the pulmonary capillary wedge pressure and 
pulmonary artery pressure, accompanied by a mild decrease of the systolic and diastolic arterial 
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pressures. [21] Studies in animal models and isolated arteries have demonstrated the specificity of 
relaxin’s acute vasodilator effect depending on the vascular territory considered. In human, the 
subcutaneous [12] and gluteal arteries showed vasodilation dependent on endothelium [22] in 
response to relaxin, but this effect was absent in myometrial and uteroplacentary arteries [23] and 
in resistance pulmonary arteries. [22] Our results have showed that relaxin does not constitute a 
potent acute vasodilator in the specific case of human MA. These findings additionally support the 
existence of local systems responsible for the action of this peptide, which might explain the 
variability of the short-term effects of relaxin in different settings. 
Pharmacotherapy seems to be able to influence the acute response to relaxin, as evidenced 
by the attenuation of the vasodilation in response to relaxin in patients medicated with ACEIs 
(angiotensin-converting-enzyme inhibitors), which was further exacerbated when the patients 
were also on indomethacin. [22] Our population, in accordance to the usual characteristics of 
patients subjected to CABG, is prominently elderly, polymedicated and with several comorbidities. 
Effectively, a large proportion of patients was on ACEIs and/or ARAs (angiotensin II receptor 
antagonists) (70,3%) and the study characteristics does not allow us to exclude a possible 
interference of these drugs on the acute effect of relaxin. The expansion of the in vitro studies with 
human arteries and veins aiming to explore possible interactions will further clarify the relevance 
of concomitant presence of pharmacologic substances on the vascular effects of relaxin. 
Alongside the acute effects, relaxin seems able to induce sustained vasodilation in human [8, 
21], compatible with the modulation of MA’s vascular function by a 24h incubation with relaxin 
that we observed. This prolonged effect may be partially explained by the apparent absence of 
classical regulation of RXFP1, which is not subjected to phosphorylation, desensitization or 
internalization with exposure to high relaxin concentrations [24]. The downstream signalling also 
seems to be different depending with the exposure duration. Relaxin activates metalloproteinases 
(MMPs) with the ability to induce endothelin-1 functional antagonism through an increase in 
endothelial ET-B signalling, with the MMP-9 being most relevant in an acute setting and MMP-2 
when the exposure is prolonged several days [25, 26]. In a prolonged exposure setting the vascular 
remodelling promoted by relaxin has an essential role, despite occurring only in certain vascular 
territories, in rat and mice [19, 27, 28]. Relaxin’s subacute and chronic vasodilatory effects seem 
to indeed rely on mechanisms distinct from those responsible for their acute effects and to vary 
depending on the specific vessel considered. 
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Studies in human tissues that corroborate the mechanisms that, in animal models and cell 
culture, are responsible for the non-acute effects of relaxin are scarce. The study of the 
mechanisms behind the chronic vascular actions of relaxin in humans bears intrinsic problems. We 
focused on the subacute effects of relaxin on a human vascular territory selected for its clinical 
relevance. It is important to note that endothelium removal did not abolish the influence of the 
treatment with relaxin on MA, which corroborates in an original way the presence of endothelium-
independent mechanisms as part of relaxin’s action on MA. Effectively, despite most experimental 
evidence both in human and in animal models pointing towards endothelium-dependent relaxin 
vascular effects, most of these studies are specifically analysing relaxin’s role in an acute setting. 
Furthermore, our study reveals no influence on vasoconstriction in response to 
phenylephrine, endothelin-1 and angiotensin II by previous incubation with relaxin, going against 
studies in rat, in which infusion of relaxin throughout 6h promoted a diminished response of 
mesenteric and aorta arteries to endothelin-1 [29] and in vivo antagonism of angiotensin II effects 
on peripheral vascular resistance [30], justifying the importance of further characterizating the 
vascular structural and molecular changes induced by relaxin in a context of subacute exposure. 
In conclusion, the present study demonstrates that previous exposure to relaxin is able to 
modulate, at least partially through endothelium independent mechanisms, MA’s vasoreactivity, 
potentiating its vasodilation with no concomitant effects on vasoconstriction. This allows us to 
state that relaxin has an interesting profile of functional effects on human mammary artery, the 
preferred conduct for myocardial revascularization. 
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